Another historic milestone in #bladdercancer treatment delivered by Tom Powles. Last year at #ESMO23 his data displaced #chemotherapy as the standard 1L tx for metastatic disease. This year at #ESMO24 his data displaces the paradigm of #neoadjuvant chemotherapy alone by showing

NIAGRA presented #ESMO24 and published today NEJM – huge accomplishment 1000+ patients enrolled. Exciting results! Some thoughts on applying them to practice...

Take home: For those still using GC x 4 cycles as NAC, practice should change to add Durva to GC pre and 8 cycles post. For those using DDMVAC, similar results can be achieved while saving IO for adjuvant using a risk adapted approach based on pathologic stage.

Nivolumab + chemoradiotherapy in pts with MIBC #bladdercancer not undergoing cystectomy👉A phase II, randomized study by the Hellenic GU Cancer Group👉encouraging improvement in disease free- and overall survival. ESMO - Eur. Oncology #ESMO24 Congrats! OncoAlert UroToday.com Hellenic Oncological Society of Diaspora-HeL.O.DI

Great talk from Teresa Alonso Gordoa at #ESMO24 on systemic therapy for #kidneycancer key points around toxicity (see comparison across pivotal 1L studies below), innovative studies investigating novel schedules (eg TIDE-A by Roberto Iacovelli, now in European Urology), 2L therapy (w up-to-date

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors | New England Journal of Medicine nejm.org/doi/full/10.10… Directly from ESMO - Eur. Oncology to NEJM 🙌🏼🙌🏼

The most elegant way to step up to the podium at #ESMO24!!! Ramon Salazar rocking!!!! Grupo GETNE always present. Big congrats!!!!🥂🍾 Jaume Capdevila J Hernando Paula Jimenez Fonseca supporting from the first row!!!@Netespana SEOM ESMO - Eur. Oncology

Primera foto de familia del grupo de TNE y Tumores Endocrinos de Vall d’Hebron Institute of Oncology (VHIO) en #ESMO24 Muy orgulloso de trabajar con esta pequeña familia 🤩 Por muchos éxitos futuros‼️

#SunRISe-4 trial explores #TAR-200 and cetrelimab combination for #BladderCancer treatment. Andrea Necchi and Zach Klaassen discuss study results showing promising efficacy for the combination therapy and the importance of multidisciplinary care > bit.ly/4de1r6y #ESMO24

Disitamab vedotin: Promising HER2-targeted therapy for #Urothelial cancer. Matt Galsky and Zach Klaassen to discuss preliminary results from RC48G001 Study Cohort C, and the importance of HER2 and FGFR3 biomarker testing > bit.ly/3MOH1GB #ESMO24

Honored to discuss 1L urothelial treatment with the great Michiel van der Heijden. Thanks #ESMO24 OncoDaily associazionepalinuro Rebecca Johnson

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer is the 1st perioperative immune therapy study to show an OS in bladder cancer. Published in @nejm gbr01.safelinks.protection.outlook.com/?url=https%3A%…

Enrique Grande Honored to be one of the authors of this abstract. One important thing to raise attention to is that patients who completed all four cycles of TAR-200 achieved a 50% pCR rate! Very important to work on patients’ compliance with this therapy! Great things coming in #bladdercancer

Recién llegados de #ESMO24, ya está todo listo para el postESMO del GrupoCentroGU. El 24 de septiembre desde las 16:30h en el Eurobuilding. Ha sido un ESMO con muchas novedades, ¡no te lo pierdas! Inscripción gratuita aquí: intranet.pacifico-meetings.com/GescoWeb/?cfg=…

Loved the unique opportunity to meet & exchange ideas w friends outside of my specialty at #ESMO24 incl H. Jack West, MD, FASCO, ASCO LDP classmates leorahornmd, Neelima Denduluri & Bradley McGregor, Heather McArthur, MD, MPH, Vivek Subbiah, MD, Zhen Su, MD; MBA & so many others not pictured here! A terrific mtg & looking fwd

PRESS RELEASE: Treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following surgical removal of the bladder, according to results from a large clinical trial. go.nih.gov/EKcC7UN

This MA supports EFS as a surrogate for OS in #MIBC after neoadj. tx ▶️Strong association of EFS + OS for treatment effects (R2 0.94) + survival outcome ▶️Significant association btw 1 yr EFS/3 yr OS, 3 yr EFS/5 yr OS, median EFS/OS #BladderCancer #ESMO24 OncoDaily Cora Sternberg

Identification of #BladderCancer pts that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA testing: Preliminary results from the #TOMBOLA trial. Presented by Jørgen Bjerggaard. #ESMO24 written coverage by Rashid K. Sayyid > bit.ly/3B40Pmy

⚡️ Immunotherapy after surgery helps people with high-risk bladder cancer live cancer-free longer #BladderCancer #Immunotherapy NIH nih.gov/news-events/ne…

NIAGARA shows that perioperative durvalumab plus neoadjuvant chemotherapy significantly improves event-free survival and overall survival in patients with muscle-invasive bladder cancer compared to neoadjuvant chemotherapy alone. NEJM Tom Powles #ESMO24 @oncoalert ESMO - Eur. Oncology